BPC-157
Availability Not yet prescribable · sold for research use only
What it is
BPC-157 is a synthetic pentadecapeptide, a chain of fifteen amino acids based on a sequence isolated from human gastric juice. It is the most discussed repair peptide in the longevity market, sold for tendon, gut, and soft-tissue healing, and it has never been an approved drug in any country.
Why people take it
Injury is the interruption that ends a training streak, and BPC-157 arrived with an unusually vivid animal literature: tendon, ligament, muscle, and gut lining healing faster in rodents. People reach for it after a stubborn tendon problem or a gut flare, wanting the repair timeline shortened rather than an abstract anti-aging effect.
How it's delivered
Some clinics advertise BPC-157 as a subcutaneous injection, sometimes near the affected area, or as an oral capsule for gut complaints. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection, oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing BPC-157; its Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. Because no approved product exists, everything about a given vial, purity and sterility included, traces back to the pharmacy or vendor behind it rather than to a label a regulator reviewed.
Where the evidence stands
The animal record is broad and the human record is close to empty. The peptide's Croatian discoverers described a controlled ulcerative-colitis trial reported in a 2005 meeting abstract, but detailed results were never published in a peer-reviewed journal, and no adequately powered independent trial has replaced them. The regulatory picture keeps moving: FDA blocked compounding in 2023 by placing BPC-157 in Category 2 of its interim bulk substances list and removed it in April 2026 after the nominations were withdrawn. In October 2026 HHS posted the draft interim compounding policy described above; it is not an approval and adds nothing to the evidence. Separately, WADA names BPC-157 among prohibited non-approved substances, banned at all times.
Estimated cost
- No approved product and no verified reference price
- Not covered by insurance
Who offers it
We don't list providers for BPC-157. There is no approved product, and we haven't verified any provider against the conditions of HHS's draft October 2026 interim compounding policy. Anything sold online as a research chemical is outside that policy.
Go deeper
The compound page, BPC-157 in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Muscle Repair and Injury Recovery, covers rehab pairing, anti-doping exposure, and how to read a repair claim.
Longevity.io is for educational purposes only and is not medical advice. Whether BPC-157 belongs in a plan is a conversation for a clinician who knows the whole picture. Confirm eligibility, product source, and pricing directly with any provider.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
